The results showed that XAB2 knockdown increased CRC cell sensitivity to oxaliplatin, as evidenced by lower half-maximal inhibitory concentration (IC50) values and a higher apoptotic rate (Fig. 3D and F). The gene discussed is XAB2; the disease is colorectal carcinoma.